Related Experiment Video
Updated: Jul 9, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Molecular pathobiology of gastrointestinal stromal sarcomas
Christopher L Corless1, Michael C Heinrich
1Department of Pathology, Oregon Health & Science University Cancer Institute, Portland, OR 97239, USA corlessc@ohsu.edu
Abstract:
Gastrointestinal stromal tumors (GISTs) form an interesting group of sarcomas whose unique pathobiology provides a model of how molecularly targeted therapeutics can have a major impact on patient welfare. Approximately 85% of GISTs are driven by oncogenic mutations in either of two receptor tyrosine kinases: KIT or platelet-derived growth factor receptor alpha. We review the pivotal relationship between specific mutations in these kinase genes, the origin and pathologic spectrum of GISTs, and the response of these tumors to treatment with kinase inhibitors such as imatinib and sunitinib. Mechanisms of resistance to kinase inhibitor therapy are discussed, and targets for the next generation of therapeutics are considered. The rapid evolution in our understanding of GISTs, which stems directly from the close alliance of basic and clinical researchers in the field, illustrates the growing role of the molecular classification of solid tumors in the development of modern oncological treatments.
Insights
Gastrointestinal stromal tumors (GISTs) are often driven by KIT or platelet-derived growth factor receptor alpha mutations. Understanding these mutations guides targeted therapies like imatinib, improving patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GISTs) represent a significant group of sarcomas.
- Their unique pathobiology serves as a model for molecularly targeted therapeutics.
- Approximately 85% of GISTs are driven by mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA).
Purpose of the Study:
- To review the relationship between specific gene mutations and GISTs.
- To discuss the response of GISTs to kinase inhibitors.
- To explore resistance mechanisms and future therapeutic targets.
Main Methods:
- Literature review of GIST pathobiology.
- Analysis of molecular drivers (KIT and PDGFRA mutations).
- Examination of treatment responses to kinase inhibitors (imatinib, sunitinib).
Main Results:
- Specific mutations in KIT and PDGFRA are pivotal to GIST origin and spectrum.
- Kinase inhibitors like imatinib and sunitinib demonstrate significant impact on GIST treatment.
- Mechanisms of resistance to therapy are being identified.
Conclusions:
- The molecular classification of GISTs is crucial for developing modern oncological treatments.
- Targeted therapies based on specific mutations have greatly improved patient welfare.
- Continued research into resistance mechanisms will inform next-generation therapeutics.
